Clinical trial
A Phase II Clinical Trial Evaluating Ipilimumab and Nivolumab in Combination for the Treatment of Rare Gastrointestinal, Neuro-Endocrine and Gynaecological Cancers
NCT02923934 is registered in ClinicalTrials.gov with Olivia Newton-John Cancer Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Clinical Trial Evaluating Ipilimumab and Nivolumab in Combination for the Treatment of Rare Gastrointestinal, Neuro-Endocrine and Gynaecological Cancers
- Lead sponsor
- Olivia Newton-John Cancer Research Institute
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 22, 2017
- Completion date
- December 12, 2023
- Enrollment
- 120 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
gastrointestinal cancer, malignant female reproductive system neoplasm, neuroendocrine tumours